Coeliac disease: a biopsy is not always necessary for diagnosis.

abstract：BACKGROUND:Health-related quality of life (HRQL) is often diminished in patients with ulcerative colitis. AIM:To evaluate the effects of vedolizumab on HRQL in patients with ulcerative colitis. METHODS:Using maintenance phase data from the GEMINI 1 study, an analysis of covariance model was used to calculate mean dif...

journal_title：Alimentary pharmacology & therapeutics

authors： Feagan BG,Patel H,Colombel JF,Rubin DT,James A,Mody R,Lasch K

更新日期：2017-01-01 00:00:00

abstract：BACKGROUND:[corrected] A predictable consequence of cholestasis is malabsorption of fat-soluble factors, (vitamins A, D, E, K) and other free radical scavengers, such as carotenoids. It has been suggested that oxygen-derived free radicals may be involved in the pathogenesis of chronic liver damage. AIMS:(i) To evaluat...

journal_title：Alimentary pharmacology & therapeutics

authors： Floreani A,Baragiotta A,Martines D,Naccarato R,D'odorico A

更新日期：2000-03-01 00:00:00

abstract：BACKGROUND:A lack of reliable treatments for abdominal pain-related functional gastrointestinal disorders prompts interest in new therapies. AIM:To evaluate systematically the effect of Lactobacillus rhamnosus GG (LGG) for treating abdominal pain-related functional gastrointestinal disorders in children. METHODS:MEDL...

journal_title：Alimentary pharmacology & therapeutics

authors： Horvath A,Dziechciarz P,Szajewska H

更新日期：2011-06-01 00:00:00

abstract：BACKGROUND:Much recent effort has been made to produce selective inhibitors of cyclo-oxygenase-2 (COX-2) in the belief that these will lack the gastrointestinal damaging effects of traditional non-steroidal anti-inflammatory drugs (NSAIDs). Inflammatory bowel disease is associated with increased local production of pro...

journal_title：Alimentary pharmacology & therapeutics

authors： McCartney SA,Mitchell JA,Fairclough PD,Farthing MJ,Warner TD

更新日期：1999-08-01 00:00:00

abstract：BACKGROUND:Little is known about the distinctive characteristics of subjects with frequent (at least weekly) and occasional gastro-oesophageal reflux symptoms. AIM:To compare the characteristics and disease management of subjects complaining of at least weekly and less frequent gastro-oesophageal reflux symptoms. MET...

journal_title：Alimentary pharmacology & therapeutics

authors： Bretagne JF,Honnorat C,Richard-Molard B,Caekaert A,Barthélemy P

更新日期：2006-03-01 00:00:00

abstract：BACKGROUND:Omeprazole maintenance therapy for gastro-oesophageal reflux disease (GERD) has been associated with an increased incidence of atrophic gastritis in H. pylori-infected patients and with a decreased absorption of protein-bound, but not of unbound cobalamin. AIM:: To test the hypothesis that the combination o...

journal_title：Alimentary pharmacology & therapeutics

authors： Schenk BE,Kuipers EJ,Klinkenberg-Knol EC,Bloemena EC,Sandell M,Nelis GF,Snel P,Festen HP,Meuwissen SG

更新日期：1999-10-01 00:00:00

abstract：BACKGROUND:Anti-tumour necrosis factor α (anti-TNF) agents have been implicated in drug-induced liver injury. There is minimal data on this occurrence in inflammatory bowel disease (IBD) patients. AIM:To identify the characteristics of liver enzyme elevations following anti-TNF therapy initiation in IBD. METHODS:A re...

journal_title：Alimentary pharmacology & therapeutics

authors： Shelton E,Chaudrey K,Sauk J,Khalili H,Masia R,Nguyen DD,Yajnik V,Ananthakrishnan AN

更新日期：2015-05-01 00:00:00

abstract：:To commemorate Edkins' discovery of gastrin in 1905, we review a century of progress in the physiology and pathobiology of gastrin and acid secretion especially as it pertains to clinical aspects of gastro-oesophageal reflux disease. Although initially ignored, Edkins' observations eventually led to the enthusiastic i...

journal_title：Alimentary pharmacology & therapeutics

authors： Malfertheiner P,Fass R,Quigley EM,Modlin IM,Malagelada JR,Moss SF,Holtmann G,Goh KL,Katelaris P,Stanghellini V,Talley NJ,Tytgat GN,Wright NA

更新日期：2006-03-15 00:00:00

abstract：BACKGROUND:Direct comparisons are lacking between vedolizumab and tumour necrosis factor (TNF)-antagonist therapy in Crohn's disease (CD). AIM:To compare safety and effectiveness of vedolizumab and TNF-antagonist therapy in adult CD patients. METHODS:Retrospective observational cohort (May 2014-December 2017) propens...

journal_title：Alimentary pharmacology & therapeutics

authors： Bohm M,Xu R,Zhang Y,Varma S,Fischer M,Kochhar G,Boland B,Singh S,Hirten R,Ungaro R,Shmidt E,Lasch K,Jairaith V,Hudesman D,Chang S,Lukin D,Swaminath A,Sands BE,Colombel JF,Kane S,Loftus EV Jr,Shen B,Siegel CA,

更新日期：2020-08-01 00:00:00

abstract：BACKGROUND:Delayed gastric emptying, impaired gastric accommodation to a meal and hypersensitivity to gastric distension have been implied in the pathophysiology of functional dyspepsia. Dyspeptic patients are often treated with the prokinetic drug cisapride. AIM:To assess the effects of cisapride on perception of gas...

journal_title：Alimentary pharmacology & therapeutics

authors： Tack J,Broeckaert D,Coulie B,Janssens J

更新日期：1998-08-01 00:00:00

abstract：BACKGROUND:The effects of proton pump inhibitors and Helicobacter pylori infection on the distribution of drugs used for the eradication of the bacteria are poorly understood. AIM:The aim of this study was to investigate the effects of a 7-day administration of 20 mg of omeprazole on the pharmacokinetics of amoxicilli...

journal_title：Alimentary pharmacology & therapeutics

authors： Ortiz RA,Calafatti SA,Corazzi A,Souza JM,Deguer M,De Souza CA,Marchioretto MA,Bernasconi G,Ferraz JG,Pedrazzoli J Jr

更新日期：2002-06-01 00:00:00

abstract：BACKGROUND:There are conflicting reports on the role of gastro-oesophageal reflux disease (GERD) and Helicobacter pylori infection in the aetiology of carditis. AIM:The role of reflux and H. pylori infection in causing carditis was assessed in 113 consecutive patients with GERD and in 25 controls. METHODS:All subject...

journal_title：Alimentary pharmacology & therapeutics

authors： Zentilin P,Mastracci L,Dulbecco P,Gambaro C,Bilardi C,Ceppa P,Spaggiari P,Iiritano E,Mansi C,Vigneri S,Fiocca R,Savarino V

更新日期：2004-06-15 00:00:00

abstract：BACKGROUND:Several measures have been used to assess the health-related quality of life (HRQoL) of patients with eosinophilic oesophagitis (EoE). AIMS:To systematically review these HRQoL measures, to appraise measurement properties of specific instruments and to evaluate determinant factors influencing HRQoL in paedi...

journal_title：Alimentary pharmacology & therapeutics

authors： Lucendo AJ,Arias-González L,Molina-Infante J,Arias Á

更新日期：2017-08-01 00:00:00

abstract：BACKGROUND:Abnormal barrier function may be genetically determined in Crohn's disease. AIM:To examine the role of abnormal intestinal permeability in genetic predisposition in multiplex vs. sporadic Crohn's disease families. METHODS:Intestinal permeability was measured in patients, relatives and partners by means of ...

journal_title：Alimentary pharmacology & therapeutics

authors： D'Incà R,Annese V,di Leo V,Latiano A,Quaino V,Abazia C,Vettorato MG,Sturniolo GC

更新日期：2006-05-15 00:00:00

abstract：:Gastric acid suppression is the most effective medical therapy to control acidic gastro-oesophageal reflux: individuals in whom therapy fails usually have inadequate acid suppression. Twenty-four-hour intragastric pH-metry measures the percentage of time that gastric pH is above 4 or 3, the critical thresholds for tis...

journal_title：Alimentary pharmacology & therapeutics

authors： Hatlebakk JG

更新日期：2003-02-01 00:00:00

abstract：BACKGROUND:Proton pump inhibitor (PPI) use may alter the gut microbiome and increase the risk of cholangitis. However, the association of PPI use with the risk of incident cholangitis has not been evaluated. AIM:To evaluate whether PPI use was associated with a higher risk of cholangitis. METHODS:This cohort study in...

journal_title：Alimentary pharmacology & therapeutics

authors： Min YW,Kang D,Shin JY,Kang M,Park JK,Lee KH,Lee JK,Lee KT,Rhee PL,Kim JJ,Guallar E,Cho J,Lee H

更新日期：2019-10-01 00:00:00

abstract：BACKGROUND:Non-cardiac chest pain is a common condition affecting approximately one-quarter of the population during their lifetime, but the long-term economic costs of non-cardiac chest pain are poorly defined. METHODS:A MEDLINE and Current Contents search was performed from 1991 to 2002 using specific keywords. All ...

journal_title：Alimentary pharmacology & therapeutics

authors： Eslick GD,Coulshed DS,Talley NJ

更新日期：2002-07-01 00:00:00

abstract：BACKGROUND:The long-term outcome of percutaneous acetic acid injection (PAI) and percutaneous ethanol injection (PEI) for treating small hepatocellular carcinoma (HCC) remains unclear. AIM:To compare the long-term outcome of PAI vs. PEI for treating small HCC. METHODS:From July 1998 to July 2004, 125 patients with sm...

journal_title：Alimentary pharmacology & therapeutics

authors： Tsai WL,Cheng JS,Lai KH,Lin CP,Lo GH,Hsu PI,Yu HC,Lin CK,Chan HH,Chen WC,Chen TA,Li WL,Liang HL

更新日期：2008-08-01 00:00:00

abstract：BACKGROUND:One-week proton pump inhibitor-based triple therapies are very popular in the US despite limited US data documenting efficacy. We assessed 1-week proton pump inhibitor triple therapies for Helicobacter pylori, and compared them to dual antibiotic therapies (to assess benefit of omeprazole) and to omeprazole-...

journal_title：Alimentary pharmacology & therapeutics

authors： Laine L,Frantz JE,Baker A,Neil GA

更新日期：1997-10-01 00:00:00

abstract：OBJECTIVE:To compare the efficacy of proton pump inhibitor vs. ranitidine bismuth citrate (RBC) with two antibiotics for 1 week in Helicobacter pylori eradication. METHODS:Randomized trials comparing 1-week regimens with (i) proton pump inhibitor plus two antibiotics [clarithromycin (C) and amoxycillin (A) or a nitroi...

journal_title：Alimentary pharmacology & therapeutics

authors： Gisbert JP,González L,Calvet X,Roqué M,Gabriel R,Pajares JM

更新日期：2000-09-01 00:00:00

abstract：BACKGROUND:Recently, there have been increasingly frequent reports on the occurrence of macrophage activation syndrome (MAS) in patients with inflammatory bowel disease (IBD). Clinically, MAS is characterized mainly by fever, hepatosplenomegaly, cytopenia, and elevated circulating ferritin and CD25. Mortality, even if ...

journal_title：Alimentary pharmacology & therapeutics

authors： Fries W,Cottone M,Cascio A

更新日期：2013-06-01 00:00:00

abstract：BACKGROUND:Hepatitis C virus (HCV) genotype 6 is common among patients from Southeast Asia and the surrounding regions, where HCV prevalence is also high. HCV genotype 6 has great genetic diversity and different response to antiviral therapy compared with the more commonly known genotype 1. AIM:Our goal was to provide...

journal_title：Alimentary pharmacology & therapeutics

authors： Chao DT,Abe K,Nguyen MH

更新日期：2011-08-01 00:00:00

abstract：BACKGROUND:Infection with the hepatitis C virus (HCV) has been considered a major cause of mortality, morbidity and resource utilisation in the US. In addition, HCV is the main cause of hepatocellular cancer (HCC) in the US. Recent developments in the diagnosis and treatment of HCV, including new recommendations pertai...

journal_title：Alimentary pharmacology & therapeutics

authors： Younossi ZM,Kanwal F,Saab S,Brown KA,El-Serag HB,Kim WR,Ahmed A,Kugelmas M,Gordon SC

更新日期：2014-03-01 00:00:00

abstract：BACKGROUND:Long-acting somatostatin analogues have been suggested as an alternative to propranolol for the prevention of variceal rebleeding. AIM:To compare the effectiveness of lanreotide SR, a new depot formulation injected once-weekly, and propranolol in reducing circadian portal blood flow (PVF) and meal-stimulate...

journal_title：Alimentary pharmacology & therapeutics

authors： Schiedermaier P,Koch L,Stoffel-Wagner B,Layer G,Sauerbruch T

更新日期：2003-10-15 00:00:00

abstract：BACKGROUND:Few studies have evaluated interferon and ribavirin therapy in hepatitis C virus-infected patients with persistently normal alanine aminotransferase (ALT) levels. AIM:To determine the efficacy and safety of combination therapy in this population, and to evaluate the impact of treatment on health-related qua...

journal_title：Alimentary pharmacology & therapeutics

authors： Bini EJ,Mehandru S

更新日期：2006-03-15 00:00:00

abstract：BACKGROUND:While current medications used to treat patients with chronic hepatitis C virus (HCV) effectively produce sustained viral response (SVR), postponement of therapy is often times attributed to patient perceptions of unfavourable outcomes. However, an instrument to assess patient perceptions of therapy (i.e. tr...

journal_title：Alimentary pharmacology & therapeutics

authors： Szeinbach SL,Baran RW,Dietz B,Gazzouola Rocca L,Littlefield D,Yawn BP

更新日期：2013-03-01 00:00:00

abstract：BACKGROUND:Bismuth compounds prevent gastric injury from the short-term administration of nonsteroidal anti-inflammatory drugs. We studied the mechanisms underlying the gastroprotective actions of bismuth subsalicylate against indomethacin-induced injury in rats. METHODS:An in vivo microscopic technique was used in wh...

journal_title：Alimentary pharmacology & therapeutics

authors： Tanaka S,Guth PH,Carryl OR,Kaunitz JD

更新日期：1997-06-01 00:00:00

abstract：BACKGROUND:Recurrent hepatitis C represents a major challenge for the liver transplant community. Given the potentially significant impact that hepatitis C recurrence has on graft and patient survival, several treatment strategies have been utilized to prevent/slow the progression to hepatitis C-related graft failure. ...

journal_title：Alimentary pharmacology & therapeutics

authors： Arjal RR,Burton JR Jr,Villamil F,Rosen HR

更新日期：2007-07-15 00:00:00

abstract：BACKGROUND:Although a few adult cases of fulminant-type autoimmune hepatitis have been reported, their clinical features and prognosis have remained uncertain. AIM:To assess the clinical features and prognosis of patients with fulminant-type autoimmune hepatitis. METHODS:Eleven patients (10%) diagnosed with fulminant...

journal_title：Alimentary pharmacology & therapeutics

authors： Miyake Y,Iwasaki Y,Terada R,Onishi T,Okamoto R,Sakai N,Sakaguchi K,Shiratori Y

更新日期：2006-05-01 00:00:00

abstract：:The effect of mefenamic acid on bowel transit time was investigated. Seven healthy adult male subjects of age 39 +/- 2.4 years (mean +/- S.E.M.) received placebo or mefenamic acid (500 mg t.d.s) orally in randomized order for five days, with a 7-day washout between studies. On the third morning after starting the drug...

journal_title：Alimentary pharmacology & therapeutics

authors： Rashid MU,Bateman DN

更新日期：1990-08-01 00:00:00